Date published: 2026-6-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

apoA Activators

Apolipoprotein A-I (apoA-I) activators encompass a diverse group of chemical compounds that enhance the functional activity of apoA-I through various mechanisms related to its central role in lipid transport and cardiovascular health. Compounds like 4-Phenylbutyrate and Probucol act to stabilize apoA-I, with the former promoting proper protein folding and the latter preserving lipid binding functionality by preventing oxidation. Retinoid X receptor (RXR) agonists such as Bexarotene and liver X receptor (LXR) agonists like GW3965 and T0901317 elevate the expression of the ATP-binding cassette transporter A1 (ABCA1), crucial for lipidating apoA-I, thereby enhancing its capacity to efflux cholesterol. Inhibitors such as Sulfosuccinimidyl oleate (SSO) indirectly support apoA-I by reducing competition for lipid binding, while Glyburide influences lipid metabolism, potentially affecting apoA-I's lipid interactions. Synthetic peptide mimetics D-4F and HDL mimetic peptide L-4F, designed to emulate apoA-I's function, directly contribute to the enhancement of cholesterol efflux and protection against lipid oxidation, complementing the natural protein's atheroprotective functions.

Additionally, novel agents like RVX-208 have been identified toincrease apoA-I production, while the Apolipoprotein A-I Milano (ApoA-IM) variant offers insight into enhanced protective functionalities of apoA-I, suggesting potential pathways for activation. Rosiglitazone, a PPARγ agonist, is involved in the upregulation of ABCA1 expression, thus facilitating apoA-I's role in cholesterol efflux. These activators ultimately collaborate to amplify apoA-I's key role in reverse cholesterol transport-a critical process in reducing the risk of atherosclerosis and associated cardiovascular diseases. Each activator, by targeting specific aspects of the biochemical pathways that apoA-I is involved in, ensures that the protein's ability to mobilize and transport lipids, particularly cholesterol, is optimized, reinforcing its essential function in maintaining lipid homeostasis and vascular health.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sodium phenylbutyrate

1716-12-7sc-200652
sc-200652A
sc-200652B
sc-200652C
sc-200652D
1 g
10 g
100 g
1 kg
10 kg
$77.00
$166.00
$622.00
$5004.00
$32783.00
43
(1)

A chemical chaperone that can enhance the stability of apoA-I by promoting proper folding, which is crucial for its role in reverse cholesterol transport.

Probucol

23288-49-5sc-203666
sc-203666A
100 mg
1 g
$79.00
$166.00
5
(1)

An antioxidant that may preserve the functionality of apoA-I by preventing the oxidation of lipids with which apoA-I interacts, thus maintaining efficient lipid binding.

Bexarotene

153559-49-0sc-217753
sc-217753A
10 mg
100 mg
$55.00
$250.00
6
(1)

A retinoid X receptor (RXR) agonist that can upregulate ABCA1 expression, leading to increased lipidation of apoA-I and enhanced cholesterol efflux.

RVX 208

1044870-39-4sc-472700
10 mg
$340.00
(0)

A small molecule that increases apoA-I production and enhances HDL cholesterol efflux capacity, indirectly enhancing apoA-I function.

Glyburide (Glibenclamide)

10238-21-8sc-200982
sc-200982A
sc-200982D
sc-200982B
sc-200982C
1 g
5 g
25 g
100 g
500 g
$46.00
$61.00
$117.00
$173.00
$530.00
36
(1)

An ATP-sensitive potassium channel inhibitor that may indirectly enhance apoA-I activity by modulating cellular metabolism and influencing lipid profiles.

GW3965

405911-09-3sc-490151
sc-490151A
sc-490151B
10 mg
50 mg
1 g
$260.00
$872.00
$1637.00
(0)

A liver X receptor (LXR) agonist that may increase apoA-I synthesis and HDL formation by upregulating ABCA1, a key regulator of cholesterol efflux involving apoA-I.

T 0901317

293754-55-9sc-202824
sc-202824A
10 mg
50 mg
$89.00
$224.00
5
(1)

Another LXR agonist with a similar function to GW3965, potentially increasing apoA-I levels and its associated lipid transport capacity.

Rosiglitazone

122320-73-4sc-202795
sc-202795A
sc-202795C
sc-202795D
sc-202795B
25 mg
100 mg
500 mg
1 g
5 g
$120.00
$326.00
$634.00
$947.00
$1259.00
38
(1)

A peroxisome proliferator-activated receptor gamma (PPARγ) agonist that may upregulate ABCA1 expression, leading to enhanced apoA-I mediated cholesterol efflux.